A Phase I clinical study of HL161 as a subcutaneous injectable.

Trial Profile

A Phase I clinical study of HL161 as a subcutaneous injectable.

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs HL 161 (Primary)
  • Indications Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Pemphigus
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Sep 2017 New trial record
    • 12 Sep 2017 According to a HanAll Biopharma media release, company is planning to initiate this trial in late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top